KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Basic) (2016 - 2025)

Sarepta Therapeutics has reported EPS (Basic) over the past 15 years, most recently at -$3.93 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 338.18% year-over-year to -$3.93; the TTM value through Dec 2025 reached -$7.02, down 386.53%, while the annual FY2025 figure was -$7.13, 388.66% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$3.93 at Sarepta Therapeutics, down from -$0.5 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $2.01 in Q2 2025 and troughed at -$5.86 in Q1 2023.
  • A 5-year average of -$1.18 and a median of -$0.81 in 2021 define the central range for EPS (Basic).
  • On a YoY basis, EPS (Basic) climbed as much as 2771.43% in 2025 and fell as far as 1310.53% in 2025.
  • Year by year, EPS (Basic) stood at -$1.43 in 2021, then grew by 13.29% to -$1.24 in 2022, then surged by 161.29% to $0.76 in 2023, then soared by 117.11% to $1.65 in 2024, then tumbled by 338.18% to -$3.93 in 2025.
  • Business Quant data shows EPS (Basic) for SRPT at -$3.93 in Q4 2025, -$0.5 in Q3 2025, and $2.01 in Q2 2025.